Where does Reven Pharmaceuticals, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Reven Pharmaceuticals, Inc. ranks #29,936 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Reven Pharmaceuticals, Inc. hold?

Reven Pharmaceuticals, Inc. holds 9 US utility patents granted between 2015 and 2021, spanning 4 technology areas.

What is Reven Pharmaceuticals, Inc.'s Innovation Score?

Reven Pharmaceuticals, Inc. has an Innovation Score of 19.8 out of 100 (6th percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is Reven Pharmaceuticals, Inc.'s patent grant rate increasing or decreasing?

Reven Pharmaceuticals, Inc.'s recent grant velocity is -50% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Reven Pharmaceuticals, Inc.'s patents?

Reven Pharmaceuticals, Inc.'s patents average 8.0 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Reven Pharmaceuticals, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Reven Pharmaceuticals, Inc.

Q: What technology areas does Reven Pharmaceuticals, Inc. focus on?

Reven Pharmaceuticals, Inc.'s top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 8 patents. Grants appear in 4 CPC subclasses total.

USPTO PatentsView assignee record - 9 granted patents across 4 technology areas, recorded in grant years 2015–2021. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Reven ranks #29,936 of 49,997 tracked US assignees by granted-patent volume, with 9 patents across 4 technology areas.

#29,936
of 49,997 US assignees by volume: 6th percentile
by Innovation Score (19.8/100): 8.0
avg claims per patent: -50%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R29936 · US Corporation #29,936 · 9 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-LOW · CLAIMS-PAR · TYPE-USCORP · VEL-DROP · BOOK-FULL

GRANTS-MICRO 9 grants
MID-PACK #29,936/49,997
PHOTO-FINISH Repeat Precision
CPC-NARROW A61P · 4 areas
INNOV-LOW 19.8/100
CLAIMS-PAR 8.0 claims/avg
TYPE-USCORP US Corporation
VEL-DROP -50% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Repeat Precision, LLC. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Qualcomm Incorporated · highest

85
Reven Pharmaceuticals · this assignee

20
3D Lighting… · lowest

7

What this shows Reven's Innovation Score is 19.8/100 (6th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Where Reven's grants concentrate

Reven Pharmaceuticals, Inc. is a focused PatentsView assignee: 4 CPC subclasses with 88.9% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2015 (3 grants) versus a trough of 1 in 2018. By volume, Reven sits between Repeat Precision, LLC. and RM2 Technology LLC.

Repeat Precision

9
Research Center F…

9
Research Institut…

9
Resh

9
Rexair

9
RF Printing

9
Ripple+

9
RM2 Technology

9
Reven Pharmaceuti… ◀

9

What this shows Reven holds 9 patents at rank #29,882, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Reven

By rank, the assignees closest to #29,882 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Reven's primary technology class.

Reven's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

20 6th percentile higher than 6% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2021

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Reven Pharmaceuticals, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	3	33.3%
2017	2	22.2%
2018	1	11.1%
2020	1	11.1%
2021	2	22.2%

Which technologies does Reven Pharmaceuticals, Inc. patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 8

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 8

A23L - Foods, Foodstuffs OR Non-alcoholic Beverages, NOT Otherwise Provided FOR; Preparation OR Treatment Thereof 3

A61Q - Specific USE OF Cosmetics OR Similar Toiletry Preparations 3

Top 4 of 4 technology areas

Where it ranks

Overall rank by patents

#29,936

of 49,997 tracked assignees

Innovation Score

19.8 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

Reven Pharmaceuticals, Inc.'s patent record in context - here's where to go next.

Reven Pharmaceuticals, Inc.'s lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 88.9% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #29,936 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Reven Pharmaceuticals, Inc. against Repeat Precision, LLC., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 19.8/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.